达安基因：间接控股股东拟变更为广药集团

Core Viewpoint - Da An Gene (002030) announced a framework agreement for the acquisition of controlling stakes involving Guangzhou Jin Kong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical Group plans to acquire or designate its wholly-owned subsidiary or related parties to acquire 100% equity of Guangyong Technology held by Guangzhou Jin Kong Group, indirectly controlling 233 million shares of Da An Gene [1] - Additionally, Guangzhou Pharmaceutical Group will acquire 70.1723 million shares of Da An Gene from Guangzhou Jin Kong Group and another 70.1723 million shares from Guangzhou Health Industry Investment through a separate agreement [1] - Upon completion of these transactions, Guangzhou Pharmaceutical Group will control a total of 26.63% of Da An Gene's shares, becoming the indirect controlling shareholder of the company [1] Group 2: Impact on Control - The successful implementation of this transaction will not result in a change of the company's controlling shareholder or actual controller [1]